In summary, TGF-β1 signaling pathway-targeted TβR1 silencing, especially when administered early in the progression of the disease, can effectively retard the pathological process and reduce the degree of hepatic fibrosis. This evidence concerns the gene TBR1 and Hepatic fibrosis.